Loading
BP2301 is an experimental autologous CAR-T cell therapy from BrightPath Biotherapeutics, in phase 1 trials for bone and soft tissue sarcoma and gynaecological cancers.
BP2301 is an autologous CAR-T cell therapy (non-viral gene transfer) from BrightPath Biotherapeutics. An autologous HER2-targeted CAR-T cell therapy made with non-viral gene transfer for HER2-expressing solid tumours. Its furthest stage is phase 1, for bone and soft tissue sarcoma and gynaecological cancers. No clinical trial naming it is registered on ClinicalTrials.gov. Company page says a phase 1 trial started in relapsed/advanced bone and soft tissue sarcoma and gynaecological cancers; no ClinicalTrials.gov entry found for BP2301 (likely a Japanese registry). It has not been shown to work in people.
An autologous HER2-targeted CAR-T cell therapy made with non-viral gene transfer for HER2-expressing solid tumours. Connects to HER2.
1.BP2301 slips into a pocket on HER2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BP2301" OR ABSTRACT:"BP2301") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BP2301, not a curated reading list.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares BrightPath Biotherapeutics and the tag pipeline.
Shares HER2 and the tag pipeline.
Shares HER2 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/